Sharon Barbari, Cytokinetics Executive Vice President of Finance and Chief Financial Officers
The first question around our opt- in. Our opt in happened with pivotal registration study, so that is the point it would be after phase 2 development. As we develop plans for pivotal registration, we would then have the option to be able to opt in and then obviously get increased milestones in royalties. If we were to do that. On the second part of your question with respect to Astellas, is it a similar type of mechanism for them. They are looking at, as we get to pivotal registration as well. They could opt in earlier though. They don’t have to wait until then until the pivotal. They have the ability to do that and then share in the economics.
Robert Blum, President and Chief Executive Officer
I just want to make sure I understood your question because it may relate differently than Sharon’s answer. With regard to other compounds rising out of the research, it is not in Astellas option mechanism rather they have those rights in our proceeding with the expectation that they would proceed in development subject to the same flows and mechanism that we have for CK107. It is not a formal option like Cytokinetics has with regards to CK107 entering late stage development. We were performing a joint research with Astellas for the last year plus with the extension of the research program are shared objective is to nominate and pursue compounds that would enter IND-enabling studies and further development as follow on to CK107 and in that regard there is an intention to proceed to development not an option to do so.
Joe Pankinis with Rob Capital Partners
Got it, now that is helpful thank you. Then maybe I guess this would be somewhat of a swing for the fences type of question but when you look at the SMA indication, I know you are willing to or it does not seem like you want to discuss the plan for the phase 2 yet but with regard to the size and what have you but based on the mathematical need, do you anticipate a call at the potential based on positive data to potentially be an accelerator to break through type of study since there are no current treatments.
Fady I. Malik, SVP, Research and Development
I think, the very 2 designations for something like this is always a potential option although I think the key is whether the data support progressing the phase 3 and pushing the mechanism forward. I think the current molecules that are in development in SMA which would be complimentary to our mechanism of action. They are embarking upon phase 3 trial now. That is the big development path I expect we would take.
Joe Pantginiswith Rob Capital Partners
Great, thanks a lot guys.
Robert Blum, President and Chief Executive Officer
I think it is important to maybe underscore something that Fady said with regard to other mechanistic approaches and then being complimentary. The other approach is that people on this call maybe familiar with and are directed to potential treatment of these patients really do relate to the genetic defect that is underline the cause of the disease where we see CK107 being potential complimentary is really to augment muscle force and increase time to muscle fatigue in particular in those adolescence and adults who have been living with this disease for longer.
